STOCK TITAN

Regencell Bioscience Holdings (RGC) 424B Filings

RGC NASDAQ

Here are the 424B prospectus supplements from Regencell Bioscience Holdings Limited (RGC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow RGC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RGC filings page.

Rhea-AI Summary

Regencell Bioscience Holdings Limited is conducting a registered direct offering of 985,222 Ordinary Shares at $20.30 per share. The offering is being sold directly to certain investors pursuant to a securities purchase agreement and a prospectus supplement dated May 19, 2026. The Placement Agent, Univest Securities, LLC, agreed to purchase 49,262 Ordinary Shares for $1.0 million and will receive cash fees equal to 6.5% of aggregate gross proceeds. Net proceeds to the company are expected to be approximately $18.4 million, intended for working capital and general corporate purposes. Shares outstanding were 494,488,908 as of December 31, 2025.

Rhea-AI Summary

Regencell Bioscience Holdings Limited proposes an at-the-market offering of up to $500,000,000 of Ordinary Shares through Univest Securities, LLC as sales agent under a Sales Agreement dated March 30, 2026. Sales may occur from time to time on Nasdaq or by other at-the-market methods at prevailing market prices.

The prospectus supplement states 494,488,908 Ordinary Shares were outstanding prior to this offering and illustrates an example where sales of up to $500,000,000 at an assumed price of $25.67 per share would increase shares outstanding to up to 513,966,897. Net proceeds are intended for working capital, capital expenditures and general corporate purposes. The filing discloses material risks including potential dilution, PFIC tax treatment for U.S. holders for the year ended June 30, 2025, and an auditor’s going-concern explanatory paragraph.